Eli Lilly earned FDA’s approval for its Reyvow (lasmiditan) tablets for the short-term treatment of migraines with or without aura in adults.

The agency granted the approval based on positive results from two trials in 3,177 adult patients. Reyvow is not indicated for preventing migraines.

“We know that the migraine community is keenly interested in additional treatment options, and we remain committed to continuing to work with stakeholders to promote the development of new therapies for the acute and preventive treatment of migraine,” said Nick Kozauer, acting deputy director of CDER’s Division of Neurology Products.